Abstract Details
|
Pablo Villoslada, MD, PhD, FÂ鶹´«Ã½Ó³»
(Hospital del Mar Research Institute)
PRESENTER |
Dr. Villoslada has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oculis. Dr. Villoslada has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bionure. Dr. Villoslada has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telara Therapeutics. Dr. Villoslada has or had stock in Attune Neurosciences.Dr. Villoslada has or had stock in Bionure Therapeutics.Dr. Villoslada has or had stock in Spiral Therapeutics.Dr. Villoslada has or had stock in Adhera Health.Dr. Villoslada has or had stock in Clarity technologies.Dr. Villoslada has or had stock in QMENTA Inc. The institution of Dr. Villoslada has received research support from Start2Cure Foundation. The institution of Dr. Villoslada has received research support from European Commission. The institution of Dr. Villoslada has received research support from Instituto Salud Carlos III. The institution of Dr. Villoslada has received research support from Focused Ultrasound Foundation and ALS Foundation. The institution of Dr. Villoslada has received research support from Caixa Foundation. Dr. Villoslada has received intellectual property interests from a discovery or technology relating to health care. |
| No disclosure on file | |
| No disclosure on file | |
| John Ko, PharmD, MS (Alnylam) | Dr. Ko has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Dr. Ko has received personal compensation for serving as an employee of Novartis. Dr. Ko has received stock or an ownership interest from Alnylam Pharmaceuticals. Dr. Ko has received stock or an ownership interest from Novartis. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file |